Novel pdms-pvp block copolymers

ABSTRACT

Methods for preparation of functionalized polyvinylpyrrolidone with polymeπzablβ functions and amphipathic polydimethylsiloxane-PVP block copolymers A (meth)acrylated polyvinylpyrrolidone compound and a (meth)acrylamide-functionalized polyvinylpyrrolidone structures are disclosed The block copolymers are useful as biomaterial components in biomedical devices They provide improved wettability, lubricity, and material compatibility to the biomedical device, e g, ophthalmic lenses

FIELD OF THE INVENTION

This invention relates to polymerizable poly(N-vinyl-2-pyrrolidone)(PVP) and amphipathic copolymers containing polydimethylsiloxane (PDMS)and polyvinylpyrrolidone. Such copolymers are of particular use ascomponents in biomedical devices such as ophthalmic applications andwound care.

BACKGROUND OF THE INVENTION

N-vinyl-2-pyrrolidone and its polymer, poly(N-vinyl-2-pyrrolidone)(PVP), is a water soluble and biocompatible polymer that has been widelyused for a range of commercial applications including for tabletbinding, hair fixation, wetting agents in ophthalmic lens formulations,membranes, adhesives, hydrophilic coatings, etc. Several methods forpreparation of functionalized polyvinylpyrrolidones have been reported,for instance using azo radical initiators in the presence of chaintransfer agents (e.g., mercaptoethanol, isopropanol, isopropoxyethanol,mercaptoethylamine, mercaptopropionic acid). See e.g. U.S. Pat. No.5,135,297 (SURFACE COATING OF POLYMER OBJECTS); U.S. Pat. No. 6,756,449B2 (AND BLOCK COPOLYMERS CONTAINING POLY (VINYL PYRROLIDONE) UNITS,MEDICAL DEVICES, AND METHODS); and US 2005/0119404 A1 (PROCESS FOR THEPREPARATION OF AMPHIPHILIC POLY (N-VINYL-2-PYRROLIDONE) BLOCKCOPOLYMERS). The disclosure of each of these documents is includedherein by reference.

It is desirable in some cases to build functionality into the PVP toprepare materials that will be retained permanently in the finalfunctional polymer device without leaching of the PVP component duringuse. For instance, (meth)acrylated or (meth)acrylamide functionalizedPVP derivatives will find utility in contact lens compositions. Inpractice, during irradiation or thermal polymerization of the contactlens mix, the functional PVP will be covalently bonded into thecrosslinked network and provide a non-leachable wettable ophthalmiclens.

Copolymers that incorporate silicone (PDMS) blocks and hydrophilicmoieties such as PVP, poly(dialkylacrylamide) (e.g.polydimethylacrylamide, polyN-isopropylacrylamide and the like), andpolyalkyleneglycol should compatibilize the hydrophobic and hydrophiliccomponents of a contact lens formulation generating optically clear andfunctional lenses. These copolymers would be useful as active componentsin applications such as silicone hydrogel lenses. In addition,amphiphilic moieties will also find use in lens care solutions targetedfor specific types of contact lens. Besides ophthalmic and lens caresolutions, other applications for the amphipathic block copolymersinclude use in tissue engineering, transdermal implants and wounddressings, industrial adhesives, sealants, surface protecting agents,drug release agents and other biomedical applications.

SUMMARY OF THE INVENTION

The present invention discloses methods for preparation offunctionalized polyvinylpyrrolidone (PVP) with polymerizable functionsand also of novel amphipathic polydimethylsiloxane—PVP copolymers. Theblock copolymers of the present invention are particularly useful asbiomaterial components in biomedical devices. Preferred embodiments ofmaterials disclosed in this invention provide improved wettability,lubricity, and material compatibility to the biomedical device (e.g. anophthalmic lens).

One generic embodiment of this invention is an amphipathic diblockcopolymer compound having the following structure:

In typical specific embodiments of that diblock copolymer, R₁ is butyl,“a” ranges from 2 to 50, R₂ is (CH₂)₃ or (CH₂)₃—O—(CH₂)₂, “b” is 1, X isO or NH, R₃ is H, R₄ is pyrrolidinone, and “d” ranges from 10 to 10,000.These novel amphipathic diblock copolymers may be formulated for use: asa lens care component for contact lenses, e.g., silicone hydrogellenses; as an oxygen permeable and wettable backing material for a woundhealing device; as a scaffold for tissue engineering; or as a componentfor controlled drug release.

Another generic embodiment of this invention is an amphipathic triblockcopolymer compound having the following structure:

In typical specific embodiments of that triblock copolymer, R₂ is (CH₂)₃or (CH₂)₃—O—(CH₂)₂, R₃ is H, R₄ is pyrrolidinone, X is O or NH, “a”ranges from 2 to 50, “b” is 1, “c” is 2, and “d” ranges from 10 to10,000. These novel amphipathic triblock copolymers may be formulatedfor use: as a lens care component for contact lenses, e.g., siliconehydrogel lenses; as an oxygen permeable and wettable backing materialfor a wound healing device; as a scaffold for tissue engineering; or asa component for controlled drug release.

Yet another generic embodiment of the present invention is anamphipathic diblock copolymer compound bearing polymerizablefunctionality, and having this structure:

In typical specific embodiments of that diblock copolymer, R₁ is butyl,“a” ranges from 2 to 50, R₂ is (CH₂)₃ or (CH₂)₃—O—(CH₂)₂, “b” is 1, X isO or NH, R₃ is H, R₄ is pyrrolidinone, “d” ranges from 10 to 10,000, R₅is C(CH₃)₂—O—CH₂—CH₂ or C(CH₃), Y is O or NH, and R₆ is CH₃. These novelamphipathic diblock copolymers may be formulated for use: as a lens carecomponent for silicone hydrogel contact lenses; as an oxygen permeableand wettable backing material for a wound healing device; as a scaffoldfor tissue engineering; or as a component for controlled drug release.

This invention also provides a (meth)acrylated polyvinylpyrrolidonecompound of the general structure depicted below.

wherein R₁ is hydrogen or C₁₋₈-alkyl, preferably H; R₂ is pyrrolidinone;n=1−10,000; R₃ is a divalent aliphatic linkage chain containing up to 8carbon atoms and up to 2 oxygen, sulfur, and/or nitrogen atoms in thelinkage chain, such as C(CH₃)₂—CH₂—CH₂, C(CH₃)₂, S—(CH₂)₂,C(CH₃)₂—O—C(═O)—NH—(CH₂)₂, C(CH₃)₂—CH₂—CH₂—O—C(═O)—NH—(CH₂)₂, orS—(CH₂)₂—O—C(═O)—NH—(CH₂)₂; and R₄ is hydrogen or C₁₋₈-alkyl, such asCH₃. In specific embodiments: R₁═H, R₃═C(CH₃)₂—O—CH₂—CH₂, R₄═CH₃, andn=10−1000; or R₁═H, R₃═C(CH₃)₂, R₄═H, and n=10−1000, or R₁═H,R₃═S—(CH₂)₃, R₄═CH₃, and n=10−1000, or R₁═H,R₃═C(CH₃)₂—O—C(═O)—NH—(CH₂)₃, R₄═CH₃, and n=10−1000. This compound issuitable for use as a polymerizable wetting agent in a contact lensformulation.

This invention likewise provides a (meth)acrylamide functionalizedpolyvinylpyrrolidone of the general structure depicted below, which islikewise suitable for use as a polymerizable wetting agent in a contactlens formulation.

In the formula: R₁ is hydrogen or C₁₋₈-alkyl; R₂ is pyrrolidinone;n=1−10,000; R₃ is a divalent aliphatic linkage chain containing up to 8carbon atoms and up to 2 oxygen, sulfur, and/or nitrogen atoms in thelinkage chain, such as S—(CH₂)_(m) wherein m is 1-6; and R₄ is hydrogenor C₁₋₈-alkyl, such as CH₃. In specific embodiments, R₁═H,R₃═S—(CH₂)_(m), “m”=1 to 6, R₄═H, and n=10−10,000 or R₁═H,R₃═S—(CH₂)_(m), “m”=1 to 3, R₄ CH₃, and n=10−10,000.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides methods for preparation of PVP withpolymerizable functionalization for use, e.g., as hydrophilic wettingagents in contact lenses. The present invention provides a new class ofcompositions of matter, comprising functionalized hybrid PDMS/polaramphipathic copolymer block systems. These materials may be used in bothindustrial and biomedical devices such as components for ophthalmicdevices (hydrogels), tissue engineering, transdermal implants,industrial adhesives, sealants, surface protecting agents, etc. Forinstance, (meth)acrylated PVP derivatives will find effective use incontact lens compositions that contain photopolymerizable components. Inpractice, during irradiation of the contact lens mix, the(meth)acrylated PVP will polymerize along with the other polymerizablecomponents to provide a non-leachable lens.

As illustrated in detail herein below, their synthesis may involvepreparing a PDMS free radical macroinitiator followed by polymerizationin the presence of N-vinyl pyrrolidone or other polar vinyl or acrylicmonomers susceptible to free radical polymerization in the presence of aCTA (chain transfer agent) such as IPA, isopropoxyethanol ormercaptoethanol to generate the OH— functionalized polymer. Theresulting polymer may be methacrylated using different chemistries byreacting the OH group with methacryloyl chloride or Methacrylicanhydride in the presence of a base or alternatively by reaction withisocyanatoethyl methacrylate.

Using this approach a variety of methacrylate (MA) functionalizedPDMS-polar copolymer blocks can be synthesized. Examples of materials ofinterest are PDMS-PVP-MAA and PDMS-polyNIPAAm-MA. The chemistry may alsobe extended to prepare difunctional methacrylate functionalized triblockcopolymers such as MA-PVP-PDMS-PVP-MA and other polymers, starting withcommercially available dihydroxy- or diamino-functionalizedpolydimethylsiloxanes. Persons skilled in the art are familiar ingeneral with the production of block copolymers having functionallyactive endgroups. For instance, U.S. Pat. No. 5,589,563 (PolymerTechnology Group), the disclosure of which is herein incorporated byreference, discloses how to make and use functionalized copolymers.

EXAMPLES Example 1 (Meth)Acrylated PVP Polymers

The synthesis of meth(acrylate) functionalized PVP is achieved by amethacrylation reaction of hydroxy functionalized PVP that is preparedusing reactions known to those skilled in the art. The general structureof polymerizable (meth)acrylated PVP may have, for instance, thefollowing formula:

The first step toward the synthesis of (meth)acrylated PVP copolymers isthe polymerization of distilled N-vinyl-2-pyrrolidone using azoinitiators such as azobis(isobutyronitrile) (AIBN) and the like in thepresence of chain transfer agents such as isopropanol, mercaptoethanol,isopropoxyethanol with or without a solvent to generate hydroxylterminated PVP of different MW's between 10,000 to 1,000,000 daltons.The resulting hydroxyl terminated PVP is converted to a terminalmethacrylate derivative using either methacryloyl chloride, methacrylicanhydride, or isocyanatoethyl methacrylate. One example of thisembodiment is synthesized using protocol shown in Scheme 1.

Example 2 (Meth)Acrylamide Functionalized PVP Polymers

Another class of polymerizable PVP is depicted below, wherein thepolymerizable functionalization is a (meth)acrylamide group.

The first step toward the synthesis of (meth)acrylamide functionalizedPVP copolymers is the polymerization of distilled N-vinylpyrrolidoneusing azo initiators such as azobis(isobutyronitrile) (AIBN) and thelike in the presence of an aminoalkylmercaptan chain transfer agent withor without a solvent to generate amino terminated PVP of different MW'sbetween 10,000 to 1,000,000 daltons. The resulting amino terminated PVPis converted to a terminal (meth)acrylamide derivative by reaction withmethacryloyl chloride, or methacrylic anhydride. One example of thisembodiment is synthesized using protocol illustrated in Scheme 2.

Example 3 Amphipathic Diblock Copolymers Including PDMS-PVP Copolymers

The present invention also provides methods for preparation of novelpolydimethylsiloxane (PDMS)—PVP copolymers and other amphipathiccopolymers of the general structure depicted in the following formula.

A retrosynthetic process for the preparation of the above class ofmatter is depicted in the following reaction scheme:

Example 4 Amphipathic Triblock Copolymers Including PVP-PDMS-PVPCopolymers

The synthetic methodology provided by the present invention also allowssynthesis of novel PVP-PDMS-PVP triblock copolymers and otheramphipathic copolymers of the general structure depicted in thefollowing formula:

A retrosynthetic approach for the preparation of the above class ofmatter is depicted in the following reaction scheme, which like that inExample 3 shows the final product preceded by the intermediates whichprovide it preceded by the starting materials.

Example 5 Monofunctional Polymerizable Amphipathic Copolymers IncludingPDMS-PVP Methacrylate Copolymers

Another embodiment of the invention is general class of compoundsbearing polymerizable functionality as depicted in the followingformula:

A retrosynthetic approach for the preparation of the above class ofmatter is depicted in Scheme 5.

As disclosed above, compositions of matter provided by the presentinvention may be used—among other things—to make silicone hydrogelcontact lenses. Persons skilled in the art are well aware in general ofmethods of manufacturing such contact lenses. Reference is made, forinstance, to U.S. Pat. No. 7,268,198 B2 (Bausch & Lomb), entitledSILICONE HYDROGEL CONTACT LENSES; to U.S. Pat. No. 6,861,123 B2,(Johnson & Johnson), entitled SILICONE HYDROGEL CONTACT LENS; and toU.S. Pat. No. 5,260,000 (Bausch & Lomb), entitled PROCESS FOR MAKINGSILICONE CONTAINING HYDROGEL LENSES.

The invention being thus described generically and with reference tospecific embodiments, it will be readily apparent to those skilled inthe art that the same may be varied in many ways. All such variationsare encompassed by the spirit of the invention, the patented scope ofwhich is demarcated in the appended claims.

1. An amphipathic diblock copolymer compound having the followingstructure:


2. The amphipathic diblock copolymer of claim 1, formulated for use as alens care component for contact lenses
 3. The amphipathic diblockcopolymer of claim 2, wherein said contact lenses are silicone hydrogellenses.
 4. The amphipathic diblock copolymer of claim 1, formulated foruse as an oxygen permeable and wettable backing material for a woundhealing device.
 5. The amphipathic diblock copolymer of claim 1,formulated for use as a scaffold for tissue engineering.
 6. Theamphipathic diblock copolymer of claim 1, formulated for use as acomponent for controlled drug release.
 7. The compound of claim 1,wherein R₁=butyl; “a” is from 2 to 50; R₂═(CH₂)₃; “b”=1; X═O; R₃═H;R₄=pyrrolidinone; and “d”=10−10,000.
 8. The compound of claim 1, whereinR₁=butyl; “a” is from 2 to 50; R₂═(CH₂)₃—O—(CH₂)₂; “b”=1; X═O; R₃═H;R₄=pyrrolidinone; and “d”=10−10,000.
 9. The compound of claim 1, whereinR₁=butyl; “a” is from 2 to 50; R₂═(CH₂)₃; “b”=1; X═NH; R₃═H;R₄=pyrrolidinone; and “d”=10−10,000.
 10. An amphipathic triblockcopolymer compound having the following structure:


11. The amphipathic triblock copolymer of claim 10, formulated for useas a lens care component for contact lenses
 12. The amphipathic triblockcopolymer of claim 11, wherein said contact lenses are silicone hydrogellenses.
 13. The amphipathic triblock copolymer of claim 10, formulatedfor use as an oxygen permeable and wettable backing material for a woundhealing device.
 14. The amphipathic triblock copolymer of claim 10,formulated for use as a scaffold for tissue engineering.
 15. Theamphipathic triblock copolymer of claim 10, formulated for use as acomponent for controlled drug release.
 16. The compound of claim 10,wherein R₃═H; R₄=pyrrolidinone; “d”=1−10,000; “c”=2; X═O;R₂═(CH₂)₃—O—(CH₂)₂; “b”=1; and “a” is from 2 to
 50. 17. The compound ofclaim 10, wherein R₃═H; R₄=pyrrolidinone; “d”=1−10,000; “c”=2; X═NH;R₂═(CH₂)₃; “b”=1; and “a” is from 2 to
 50. 18. The compound of claim 10,wherein R₃═H; R₄=pyrrolidinone; “d”=1−10,000; “c”=2; X═NH;R₂═(CH₂)₃—O—(CH₂)₂; “b”=1; and “a” is from 2 to
 50. 19. An amphipathicdiblock copolymer compound bearing polymerizable functionality havingthe following general structure:


20. The amphipathic diblock copolymer of claim 19, formulated for use inthe preparation of silicone hydrogel lenses.
 21. The amphipathic diblockcopolymer of claim 19, formulated for use in the preparation of anoxygen permeable and wettable backing material for a wound healingdevice.
 22. The amphipathic diblock copolymer of claim 19, formulatedfor use in the preparation of a scaffold for tissue engineering.
 23. Theamphipathic diblock copolymer of claim 19, formulated for use in thepreparation of a component for controlled drug release.
 24. The compoundof claim 19, wherein R₁=butyl; “a” is from 2 to 50; R₂═(CH₂)₃; “b”=1;X═O; R₃═H; R₄ pyrrolidinone; “d”=1−10,000; R₅═C(CH₃)₂—O—CH₂—CH₂; Y═O;and R₆═CH₃.
 25. The compound of claim 19, wherein R₁=butyl; “a” is from2 to 50; R₂═(CH₂)₃; “b”=1; X═O; R₃═H; R₄=pyrrolidinone; “d”=1−10,000;R₅═C(CH₃)₂—O—CH₂—CH₂; Y═NH; and R₆═CH₃.
 26. The compound of claim 19,wherein R₁=butyl; “a” is from 2 to 50; R₂═(CH₂)₃; “b”=1; X═NH; R₃═H;R₄=pyrrolidinone; “d”=1−10,000; R₅═C(CH₃); Y═O; and R₆═CH₃.
 27. Thecompound of claim 19, wherein R₁=butyl; “a” is from 2 to 50;R₂═(CH₂)₃—O—(CH₂)₂; “b”=1; X═O; R₃═H; R₄=pyrrolidinone; “d”=1−10,000;R₅═C(CH₃); Y═NH; and R₆═CH₃.
 28. A (meth)acrylated polyvinylpyrrolidoneof the general structure depicted below, suitable for use as apolymerizable wetting agent in a contact lens formulation:

wherein R₁ is hydrogen or C₁₋₈-alkyl, preferably H; R₂ is pyrrolidinone;n=1−10,000; R₃ is a divalent aliphatic linkage chain containing up to 8carbon atoms and up to 2 oxygen, sulfur, and/or nitrogen atoms in thelinkage chain, such as C(CH₃)₂—CH₂—CH₂, C(CH₃)₂, S—(CH₂)₂,C(CH₃)₂—O—C(═O)—NH—(CH₂)₂, C(CH₃)₂—CH₂—CH₂—O—C(═O)—NH—(CH₂)₂, orS—(CH₂)₂—O—C(═O)—NH—(CH₂)₂; and R₄ is hydrogen or C₁₋₈-alkyl, such asCH₃.
 29. The compound of claim 28, wherein R₁═H; R₃═C(CH₃)₂—O—CH₂—CH₂;R₄═CH₃; and n=10−10,000.
 30. The compound of claim 28, wherein R₁═H;R₃═C(CH₃)₂; R₄═H; and n=10−10,000.
 31. The compound of claim 28, whereinR₁═H; R₃═S—(CH₂)₃; R₄═CH₃; and n=10−10,000.
 32. The compound of claim28, wherein R₁═H; R₃═C(CH₃)₂—O—C(═O)—NH—(CH₂)₃; R₄═CH₃; and n=10−10,000.33. A (meth)acrylamide functionalized polyvinylpyrrolidone of thegeneral structure depicted below, suitable for use as a polymerizablewetting agent in a contact lens formulation:

wherein R₁ is hydrogen or C₁₋₈-alkyl; R₂ is pyrrolidinone; n=1−10,000;R₃ is a divalent aliphatic linkage chain containing up to 8 carbon atomsand up to 2 oxygen, sulfur, and/or nitrogen atoms in the linkage chain,such as S—(CH₂)_(m) wherein m is 1-6; and R₄ is hydrogen or C₁₋₈-alkyl,such as CH₃.
 34. The compound of claim 33, wherein R₁═H; R₃═S—(CH₂)_(m);“m”=1 to 6; R₄═H; and n=10−10,000.
 35. The compound of claim 33, whereinR₁═H; R₃═S—(CH₂)_(m); “m”=1 to 3; R₄═CH₃; and n=10−10,000.